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qh~ purpose of thi~ stud~ "as to Ideotif) "'hleh of the bIochem-
ical. immunological, or functional parameters deriled before 
suraer) IS part of • systemic enluation "ere helpful in pre-
dictin" the frequenc) of rejection episodes, the chance of sur-
vivII, and the cauSe risk of death (should death occur) of pa-
tients after orthotopic Unr transplantation (OL Tx). Ninet)-
elaht Idult pltients "'ho had an extensive preoperltive 
protocol e'alultion "ere studied before OlTx. The biocbemi-
cal parameters assessed "ere albumin. prothrombin time, bili-
rubin. and ICG clearance. The immunologic parameters as-
wssed included totlll)mpbocytes. T3 cells, T4 cells. 1'8 cells, 
and the T4[T8 ratio. The dejq~ of histocompatibilit) anti"en 
(HlA) matching be"'een the donor and the recipient "as also 
evaluated In 80 of the 98 patients studied. 
Most postoperathe deatbs ()C('\Irred within 12 "Hks of tbe 
prOCf'dure EO4~; 14 of 98 patients); 13 patients (13'l) died 
witbin the first 6 ~toperathe "Hks, of either bacterial or 
fun"al wpsis. An additional 14 patients O.c'\) died after tbe 
initial 6 postoperatile ,,«k5 due, primaril) of an acquired _inl 
and/or protozoan infection (p < 0.01). 
Durina the first 6 "HILs, lunhal "as beNer for patients 
with cbolestatic Iiler disease (OLD, 93'\, n = 45) and miseel-
laMous Iher diseases (MIse. )00'\, D = 10) thsn it lI"IS for 
those "ith parenchymal nur diseases (PLD, 77%, D = 43). 
Although albumin, prothrombin time, T4/T8 ratios, and per 
cent 1'8 cells "ere statisticall) different in patients .. itb PlD 
&5 compared "itb tbose witb OLD, tbese parameters., as well 
&5 the per cent q~ «lis, Hrum bilirubin 1elel, per cent reten-
tion of ICG at 15 minutes, and the plasma ICG disappearan« 
rate "ere not found to be of substantial belp in predictina 
patient sunhal or nonsurvhal. 
Moreoler, neither tbe dearee of HlA matching Dor tbe 
Dumber of reje-ction episodes differed be"D~n sunhina and 
DODsunhina patients. 
The results of tbis stud) suggest that patients "itb PlD are 
at increased risk of earl) postoperatiH death after OL Tx be-
cauw of bacterialll1d/or funpl wpsis, as compared with pa-
tients operated upon for OLD. SeNer prr-, Intra-, aod postop-
erathe predictors of risk of dntb and complicatloDs are 
Reprint requests and correspondence Or. M. Adler, $tn-ice de 
Gastroentrroloeie. Hopital Eri5me. 808, route de Lennik. Pr 1070 
Bn.t\cllc-s. IklJium 
Submitted for publication Febn.tal) 17. 1988. 
From the Department of M&diclne and Surgery. University of 
Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
needed to reduce the tarl)' mortalit), obwrved after ortbotopic 
Uvu transplantation. 
D UE TO A \ARIETY of factors, such as better ini-tial selection of candidates for the procedure. 
refinements in the techniques of organ pro-
curement and surgical grafting, the introduction of cy-
c1osporine A (CyA). and improvements in the pre- and 
postoperative management of such patients, the life ex-
pectanc) of patients undergoing orthotopic liver trans-
plantation (OL Tx) has increased considerabl)' over the 
last several years. I Recent data from our institution re-
garding sun;val sho .... a 69.7 and 62.8'l 1- and 5-year 
actuarial sun;val in 313 adult liver transplant patients.: 
The vast majority of the postoperative deaths have oc-
curred .... ;thin the first 2 postoperative months and are 
related primarily to sepsis. 3 Rejection is also a frequent. 
albeit controllable. problem after OL Tx. 
The intensi"'e immunosuppressive regimens used to 
treat rejection facilitate postoperative sepsis Other fac-
tors, independent of the preoperative condition of the 
patient receiving a graft, might also play an imJX)rtant 
role in contributing to some of the postoperative deaths 
observed. Examples include ischemia of the graft and 
technical problems at the time of the operation that lead 
to postoperative vascular anastomotic thrombosis. 
Because of these uncertainties, we have evaluated pa_ 
tients prospectively for liver transplant and have tried to 
identify immunologic. biochemi~I and functional pa_ 
rameters that predict the frequency of rejection epi-
sodes, the chance of sur-ivaI, and the cause of death. 
should death occur in these patients. The follo .... ;ng is a 
report of our findings. 
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Material and \1ethoct\ 
W( studlt'd all adult candidatn "ho "erc (\alu3tl'd 
for possiblt' !tvt'r transplantation bet"t'en Scptcmhcr 
1984 and September 1986 During this period. I ~l adult 
patients rec(ived transplantations at the Uni\er..ity of 
PillSburgh ~inetF -eight of these patient~ had a protocol 
preoperati\e (valuation before the transplant and "'cre 
considered for inclusion 10 the stud~K The remaining ~~ 
patients were either (valuated at their own referring in-
stitutions or were sent directly to the surg.ical service (n 
:: 42) and were (ither not evaluated completely or had 
acute hepatic failure that prohibited a complete preoper-
ative evaluation (n = 10) before transplantation. 
The indicator.. of need for Ol Tx in these 98 patients 
are shown in Table I. Overall, we can divide these 98 
patients into three distinct groups: a parenchymal liver 
disease group (PlD, n = 43), a cholestatic liver disease 
group (ChLD. n = 45), and a miscellaneous group 
(MISe. n = 10). The mean ± SEM age for the PLD 
patients was 33 ± 2 years (range = 17-59 yrs): 40 ± 2 
years for the ChlD patients (range = 20-57 yrs); and 40 
± 4 years for the MISe (range = 21-52 yrs). The ratio of 
men to women was 1.3 for the PlD group, 0.7 for the 
ChLD group, and 1.2 for the MISe group. 
The average interval between the initial evaluation 
and the subsequent OL Tx was 4 months (rang.e = I 
week-I year); the average for patients with PlD. 3.0 
± 0.6 months, was shorter than it was for patients "'ith 
ChlD, for whom it was 5.0 ± 0.6 months (p < 0.05). 
The following biochemical and immunological pa-
rameters were determined for all candidates: serum bili-
rubin and albumin levels. prothrombin time (PT), total 
lymphoC)1e count and lymphoc)1e subsets determina-
tions. and the patient's histocompatibility antigens 
(HLA). Both absolute numbers and the percentage of T 
Jymphoc,)1es and the various T lymphoc)1e subsets were 
determined The T cell subpopulations were determined 
by flow cytometf') on a FACS IV (Becton-DiclOnson. 
Mountain View. CAl, using a slight modification of the 
method described pre\;ously.' The follo",;ng fluorescent 
labeled anti-T cell surface marker monoclonal antibod-
ies were used: T3 (OKT). Ltu 4), T. (OKT •. Ltu 3 a 
+ b). and T. (OKT,. Ltu 2a). (The OKT series was 
purchased from Ortho Diagnostics; the Ltu series was 
purchased from Becton-aickKin~nKF At least 5 X 10' 
cells were analyzed for each monoclonal antibody deter-
mination. Control lymphocyte subset measurements 
were obtained in 100 contemporarily studied. normal 
patients. 
In 80 of the 98 patients studied. peripheral blood 
lymphocytes of both the donor and the recipient were 
typed for HLA A. B. and DR antigens. The method used 
included the use of the standard National Institute of 
Health microlymphoc)10toxicity technique for detec-
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tion of A and B antigens and prolonged incubation mi-
crolymphoc)10xicity testing using enriched B<ell pre~ 
arations obtained after carbonyl·iron treatment and Fi-
col\·H Hypaque sedimentation after rosetting with 
neuraminidase-treated sheep red blood cells for the de-
tection of the DR antigens. HLA matching between 
donors and recipients was considered when an antigen 
present in the donor was also present in the recipient. 
Measurement of the plasma retention of Jndoc)anine 
green (ICG) at 15 minutes and its plasma disappearance 
rate. obtained after intravenous (l.V.) administration of 
the drug. were determined in 86 of the patients 
The follo,,;ng parameters were studied after OL Tx: 
survival. cause of death. number of rejection episodes. 
hospitalization duration. the cyclosporine and predni-
sone dose (oral) given at discharge. and the last follow-
up cyclosporine and predni~ne dosage. 
In regard to sun;val. five groups of patients were con· 
sidered. Group A (n = 13) included patients dying dur-
ing the first 6 postoperative weeks; Group B (n = II) 
consisted of those d)ing between the 6th and 12th post-
operative weeks; Group C (n = 3) consisted of those who 
died after the 12th postoperative week; Group D (n 
= 39) included patients who sun;ved after a follow-up 
less of than I year. and Group E (n = 31) included 
patients who sun;ved after .. follow-up of more than I 
year. Two other patient categories were al~ evaluated: 
the 24 patients who died within 12 weeks of the trans-
plantation procedure (Groups A and B combined) and 
the 70 patients who survived at least 12 weeks after the 
operation (Groups 0 and E combined). 
A rejection episode was considered present when an 
elevation of bilirubin and/or gamma gJutamyl transpep-
tidase occurred in the absence of biliary obstruction. or 
vascular thrombosis and resolved rapidly ~;th the initia-
tion of antirejection therapy. Histologic confirmation of 
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presumed rejection w~ fr~uently obtained and was es-
tablished through the use of criteria recently reported. S 
At least one rejection episode occurred in each of 67 of 
the 98 patients studied and w~ diagnosed by clinical 
criteria in 22 (331k) and a combined c1inico-histologic 
basis in 45 (67<k). A typical antirejection regimen in-
cluded a large J.V. dose of hydrocortis.one or predniso-
lone v.ith or v.ithout a I-week steroid recycle.) Since 
August 1984, the antirejection therapy has included 
OK T 1 administration, as well. 
Before Ol Tx, aaforin (I g of IV) was given to all 
patients. Ampicillin (I g) and claforin (I g) were given 
intravenously every 6 hours for 5 days; Mycostatin was 
given orally at identical intenals. 
Twenty-seven patients died. A complete autops~ was 
obtained from 22. Generall), either the most prominent 
pathologic eV'ent found at the time of the autops) or if 
an autopsy was not performed, the most important 
compli~tion during the immediate preterminal clinical 
course was identified as the cause of death. 
Pre- and postoperative <Uta were entered in on an 
IBM"" computer. Analysis of variance (ANOV A), 
Spearman correlation, chi-square analysis, and Stu-
dent's I test for paired and unpaired values were used in 
the statistical analysis of the <Uta obtained using a Stat-
pack"'. Statistical significance was obtained when the p 
value was at least <0.05. 
Rc-sults 
Sun';}'a! 
The survival groups are represented in Table 2 as well 
as cause of death, the cause of sepsis, number of retrans-
plantation when it occurred, and the ratio of PlD/ 
ChlO cases for each group. 
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Thirteen per cent (13 of 98 patients) of the deaths 
observed occurred v.ithin 6 weeks of operation; O4~ (24 
of 98 patients) occurred within 12 weeks of the proce-
dure. Only 3% (three of 97 patients) of the deaths occur 
more than 12 weeks after the time of surgery. Sepsis was 
the principle cause (79S"c: 19 of 24 patients) of death in 
those who died v.ithin 12 weeks of surgery. Bacterial and 
fungal sepsi~ was seen as the cause of death principall) in 
those patients who died v.ithin the first 6 weeks, whereas 
viral and protozoal sepsis were the principal causes of 
death that ()(Xurred after 6 weeks (X2 = 6.6; 95% Confi-
dence Interval (Cl) 2.1-121.3; p < 0.0 I). An odds ratio 
for deaths of 16.33 was obtained, shov.ing that risk of 
earl) death (before 6 weeks) was increased sixteen-fold 
in those who de\eJoped an earl) postoperative bacterial 
and fungal infection. 
A higher frequenC) of retransplantation was seen in 
Groups A and B as compared to Groups 0 and E (14 of 
24 patients = RU~ l'S 10 of 70 patients = 14~I P < 0.05) 
Interestingly, the PLD/ChlO ratio was higher in the 
Group A patients who died of early bacterial or fungal 
sepsis as compared to any of the other four groups (X: 
= 5.1; 9R~ CII.13-32.7; p < 0.05). 
The percentage of patients operated upon for PlO, 
ChLD and MISe hepatic diseases who sun;ved at 6 
weeks, 12 weeks. and I year is shown in Figure I. There 
was a rapid decline in patient survival in the PlO group 
during the first 6 postoperative weeks as compared to 
either of the other two patient groups. Overall, the per-
centage of patients who survived at any point was bener 
for those in either the MISC or the ChLO categories 
than it was for those in the PlO group. Of particular 
interest, however, is the fact that after the initial 6 weeks. 
the survival curves for all three groups were essentially 
parallel (Fig. 1). 
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The prtDlran~rlgn: yalue~ fc'l[ lotP11~mphEFE~1e~ and T 
l~ mphoc~1ED suh~t~ arc shcm n In Tahlc ~ and are com· 
pared wIth tho~ of normal controls Throug.h thIs com· 
panson. all mononuclear su~sets v.ere found tCl be de· 
crea~d slgmficanll~ In the ll\er transplant recIpIent ... 
Ho"e.er. the 1. (helpcT)/T ~ (suppressor) ratIo v.as slg· 
nlficanll~ hIgher 10 the transplant recipients as com-
pared to the controls, because 01 a relativel) smaller 
reductlon in the numbtr of T. ceils as compared to q~ 
cells, These same pretransplant parameters separated 
the types of liver disease (PLD. ChLD. and MISe he-
patic di~asesFI These data are shown in Table 4, It is 
apparent from this tahle that. compared to normal con-
trols. patients with parenchymal liver disease had simi-
lar values for their percentage T. cells and resultant 
qK!q~ ratios. In contrast. their percentage T. cells was 
reduced modestl~ but significantl~ (Mean:! SEM: 42.5 
:! 1.9 \'S 49:f 1.0; p < 0,05). Asexpected. their albumin 
and prothrombin time values were lower than those of 
controls. as well as those within the cholestatic or mis-
cellaneous liver disease groups, 
In contrast. patients with cholestatic liver disease have 
a lower percentage ofq~ E~1ean :! SEM: 16,2S :! 1.0 rs 
24 :! 0,6; p < 0.0:;, and a resultant higher HIS ratio than 
did the controls (Mean ~ SEM, 3.4 :! 0.2 rs 2,0:! 0 I: p 
< OOOS). Their percentage T. cells was not dIfferent 
from that of the controls, 
The per cent retention of ICG at 15 minutes and 
plasma ICG disappearance rates were not different be-
tween the three fiye~ disease groups. but were markedl) 
altered as compared to normal values (Table 4 and 
Fig 2). 
Re!al/OnSnlp Be/I\{'cr. Sur./la! Croups and Ihl' J 'arious 
Asscssed ImmunologiC Biochemical and Func/ional Pa· 
ramelers Oblained bcforc Surgery 
Preoperative le\els for T.n •. percentage of T I cells. 
percentage of T. cells. bilirubin. albumin. prothrombin 
time. percentage of ICG retained at 15 minutes. and 
plasma ICG disappearance rate (k) in patients who did 
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not survive 12 weeks (n = 24) and those who did sun i\e 
after 12 weeks (n = 70) are shown in.Iahle 5. 
None of these parameters was significantly different 
between the two groups. The lCG disappearance curves 
for these two groups of patients is shown in Figure 2 and 
is compared to that of normal controls. 
llsing analysis of variance. the same parameters 'Mre 
evaluated in the fi.;e sun'ival groups Again. there were 
no statisticall~ significant differences bet"een the dIffer· 
ent survival groups. 
The degree ofHLA·A and B (Class I). HLA·DR (Oem 
II) and combined HLA·AB + DR antigen matches for 
each of the five different survi\al Jroups is shown in 
Table VI and Figure 3. ~o significant relationship was 
seen between the number of HLA matches and patien~ 
sun·ival. I n fact. what was noted was the marked lack of 
any agreement betv.een the donon, and recipients fo; 
either Class I or Class 11 antigens. Specificall). a rather 
10" number of matches was obseryed~ for example. a 
mean of 1.3, 0.9,2,0. 1.3. and 1.3 HLA.·A and B + DR 
matches out of a maximum of six possible matches 
respectively. v. as seen in Groups A through E, 
Interesting.]). no correlation was obtained between the 
number of HLA matches and the number of rejectior: 
episodes experienced Furthermore, no correlation was 
q~Bl[ 3. Prl'/forl5l'lan: I'a/ut's (.\ICOI'I ~ SEMi ofL,rml'hr)':yrcs TCtl/s rTJJ Hcll'('r Ct'II., 'T.,; SUl'l'fCSS(1f Ct'1/5 fT,) 
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Controls 1~P9! 51 O~KO :! \.0 1174!49 67 ! 0.7 T9~ ! 28 49 ~ \.0 397 ~ \ ~ 24 ! 0.6 2.0!: 0 ' 
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• plglffstlcall~ dlffcrtnl (II lusl P < ll~F fron-. PlD 
1 ptKallstlCall~ different (it Ic.ast p < ll~ I from controh 
~ 100 control p.1l1enu .... ere sludled for compamon of the tmmuno-
obtained between the number of lymphoc~1es or the 
number of various lymphoc~1e subsets and the number 
of rejection episodes experienced. the last hospitaliza-
tion dosage of CyA and prednisone. the last follow-up 
dosage ofCyA and prednisone or the duration ofhospi-
talization. Moreover, the number of rejection episodes 
did not differ between the various suni\al groups 
(Mean ± SEM: I ± 0.4 in Group A; I ± 0.4 in Group 8; 
0.3 ± 0.3 in Group C; L7 ± 0.3 in Group 0; 1.2 ± 0,2 in 
Group E). 
Discussion 
In this stud), we tried to identif) the pretransplanta-
tion-obtained immunological, biochemical and func-
tional parameters the might be of help in predicti ng the 
ultimate outcome of the procedure. Onl) those parame-
ters that could be obtained as part of a systematic rou-
tine pretransplant work-up were considered for evalua-
tion. It has been ShO .... l1 that patients .... ith hepatic failure 
due to any cause severe enough to warrant }j\er trans· 
plantation have abnormalities in the number and per-
centage of cells in each of the various mononuclear cell 
subsets As far as ~lfular immunit~ parameters are con-
cerned, patients with ChLD as compared to normal 
controls and patients .... ith PLD have significantl~ higher 
pretransplant helper-suppressor ratios. primaril~ be· 
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FIG. 2 Los plasma pcrcenlaie ICG rtlcnuon in rtlation to time in 
normal subjeru (n " 5) ti compared 10 palu:nu "'ho sunne (n '" 70) 
and thoS( "'ho do nOI 5un;vt (n ., 24) transplint.alion 
IOSKii param~teIKKIK u\ua! normii \alur< fo! alt->umln and P1 .. ~rc 
con~ldcrcd oe~ult< from fi'e normal \ul'>Jrc\ "'llhout hep,1'" ~KDr 
funulon ... cre uS(d for the ICG ck.lfancc slud,t\ 
cause of a relative reduction in the number of then T ~ 
(suppressor) cells. Moreo\er, patients .... ith PlD h~ye 
normal helper/suppressor ratios, but also have a mod~t 
reduction in the percentage of T. (helper) cells. These 
facts confirm earlier dataf.- 1 that suggest that prima~ 
biliary cirrhosis and sclerosing cholangitis behave like 
other autoimmune diseases and ha .. e an increased 
helper-suppressor cell ratio It is presumed. although not 
established, that this occurs because the T. cells )e4\e 
the vascular compartment to colonize the liver and ac-
cumulate and exert their effects at the site of their \afiet 
antigens .... ithin the liver.' 
Blochemicalg~K the patients with PlD considerec for 
transplantation present .... ;th lower albumin and more 
abnormal prothrombin times as compared to patients 
..... ith ChlD. On the other hand. hepatic function ~ de-
termined by indocyanine green clearance did not differ 
between the two groups Patients .... ith ChLD had a bet-
ter sun-iva) rate than did patients .... ith PLD. Thw 6-
week. 8-week. and I-Ye4r sUf\ival figures of pa:K~nts 
.... ith ChLD are 9P~K 82";:. and TP~K respectiyDeF~-in 
contrast .... ith those of patients .... ith PlD who ha\e sur-
\;\als of 771ft, SR~K and RT~ at these same respe;;l\e 
time points It is also evident from our data tha: thiS 
difference is caused principal)) by an increased nu:;:ber 
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FIG 3. Compamon lxl"D~n sunwal "oups and dqt((' of prt~fDinyK­
planl HlA malches "'llh donor (mean:! SEM) (n " 82) 
of p0sl()perall\e deaths occumn~ in palients with PLD 
v.lthln the fl~1 f. postoperalj\e w{'eh 
O\erall. mortaht~ in the presenl sEf"ie~ was OT~ (27 of 
9g patients). most of which occurred during the fi~t I ~ 
postoperati\e v.eeks It should also be emphasized that 
among Ihe Group A pallents (those dying within 6 
weeks of operation). tWice as man~ patients had PLO as 
had ChLO. v. hereas a ratio of less than one was present 
in the four other survival groups Moreover. bacterial. 
and fungal sepsis were the two major causes of death In 
the Group A patients. 
It is not unreasonable to think that the mechanisms 
responsible for protecting the indhidual against bacte-
rial infection that are particularly deficient in patients 
with advanced PlO as compared to ClO normalize 
with the successful engraflment of a functioning liver. 
However. as graft dysfunction frequently persists. at 
least to some degree. during the first 2 postoperative 
weeks, it is also probable that any pre-existing abnor-
mality in host defense mechanisms will persist or be-
come even less effective for a short period after Ol Tx. 
thereby rendering the patient even more susceptible to' 
bacterial and/or fungal sepsis. Because it has been 
shown to influence cellular immune response mecha· 
nisms.9tO poor nutrition could also be implicated and 
could aggravate a pre-existing reduction in helper cell 
function present in liver transplant patients. occurring 
as a consequence of either their primary hepatic disease 
or the immunosuppression therapy that the)' reQuire. 
The fact that a reduced serum albumin level is related 
to greater blood losses experienced during the first phase 
(dissection) of OL T). procedure l' and that the preopera· 
tive coagulation profile is more severely altered in pa-
tients v.ith PLO than it is in patients .... ith ChLD. ,; is 
consistent also v.ith the observation of a greater postop-
erative mortalit:- in patients .... ith parenchymal liver dis-
ease than those .... ith cholestatic liver disease. It remains 
to be shown howe\er that the preoperative correction of 
preexisting nutritional abnormalities present in PlO pa-
tients improves the survlval of these patients follo .... ing 
OlTx. 
Unfortunately, immunological biochemical and 
functional parameters of liver function obtained before 
~EI I 
'''8it ~ EElnir~mfy 0-; 8,·· ... (.·,./.: .. ·1(1(; \ " . .. r,,\,,'\o":t1J .... "'f. 
prr"yiyffD~ '" 7,"n; I" P'C·;' __ ''';lr.'",'r.' I (; ~j (.' 7, 7, .. 74 {('.' 
'l! T~ (el" BIilDDD·K~ 1:~~M:IC f'J ~ I( (, RfI,·n:j",. \, o~K: 
ICC, DI DD:;I~IMCK1DKgrK .• R.Jt. D~ ('fcu' ~ 51. \f 
I:· .... ~K I:· ..... ~rlK 
"'on\u.-,,, or, Sun l\ ('" r 
(n ' :~i In : i(1I \ ~lu~ 
l.n. : " ::: 03 30 ~ 0 : "I" 
'I T. ~1f~ 4,) 4 ~ 2 ~ 43 Ii ~ I f, II~ 
'I T. ~1f~ :(1 (I ::: U 166 : t' II "'.., 
Bilirubin (m& dll I' , =- 30 I ~ 3 ! 40 "D~ Albumin (&'dl, e~ ::: 0 I: 30 ! 0 l~ !'liS 
P1 ('\) 71:0 0 ~ 2.0 82.0 ~ ~ 0 "'s 
X, ('li) 508 ~ 3 ~ 4/3 ! 2 ~ ",S 
11 (min' ') () 0 I: ::: 000: 00) ~ ::: 0 ttll~ ",5 
NS = no ~fi:nlficanl difference 
surgery do not appear to help substantiall~ in predicting 
sur,ival after OL Tx. When comparing patients .... ho 
survive for greater than 12 weeks (those in Groups D 
and E) with the patients who survive less than 12 .... eeks 
(those in Groups A and B). no differences in the levels of 
albumin, bilirubin. prothrombin time. T4fT. ratio. per· 
centage ofT ~ cells. percentage ofT@ cells. and the plasma 
leG disappearance rate were evident. HO\l,C\er. II 
should be pointed out that the deaths that occuned afler 
the initial 6 weeks occurred primarily as a result of a 
viral or protozoal infection and are. most like!). a con-
sequence of the immunosuppression used. rather than a 
conseQuence of some pre-existlOg biological or immu-
nological \'ariable determined before surgery that ma~ 
exist in the stud~ population. 
Ho",e\er. despite hov. dissatisfying the present data 
are. the~ do identif~ paramete~ that do not appear to be 
involved in determlTling sUl"\ival after OL h-that is. 
the number of rejection episodes andlor the number of 
HLA mismatches This is true despite the facl that it IS 
generall~ held that the HlA antigens of Class ) (A.. B) 
and Class 11 (DR) loci are thOUght to be strong trans-
plantation antigens and to play an important role in the 
initiation of the rejection process. 
A recent publication on more than 8000 kidne) 
transplant procedures collected from allover the world 
documents the relationship between sUl"\ival and the 
TABLE 6 Compar/JOI1 Btlto ern puryDl~of Groups a>Ui Dtg'tr of PrtlrOfIJplanl H L.f .\fa/du's "lIh D(JnN (Mean::: Sf'!· (n = 8.', 
Group A Group B Groupe Group D Group E 
In'" 10) In = II) (n '" 3) (n" 27) (n '" 21) 
HLA-AB 
(perfect match'" 40) 0.9 ~ 0.3 0.6 ~ 0.2 13 ~ 03 U ~ 0.2 o 9 ~ 0 ~ 
Hl. .. ·DR 
(perfect malch = 20) 0.4 ~ 0.1 0.3 ~ 0.2 0.7 ~ 03 o 15 ~ 01 l~ ~ 0.1 
HLA·AB .. DR 
(perfect match = 60) 1.3 ~ 0.4 0.9 ~ 0.3 2.0::: 0.5 1.3 ~ 0.2 J.3 :! 02 
~o~ 
dep~ of HLA. matching In kljil{I~ transplantatIOn I' 
Celr;nl~ it IS po~~ihlc that the smaller numher ofOl Tx 
cases studied and the deliberate failure to search for the 
best possible match In Ji\er transplant cases arc impor. 
tant clements that contribute to the dlfferen~ observed 
bet\l,een kidne:- and Iner traml'lant .. ti0n data relative to 
this Issue. 
Considering all of the data a\ailable. the present stud) 
highlights the overall good results experienced with 
Ol T>. for end-stage liver disea!){' and (ontributes to the 
gro\l,lng confidence in pursuing liver tram-plantation as 
the treatment of choice for a variety of h\er dIseases v.ith 
irreversible advanced hepatic failure. 
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